USA flag logo/image

An Official Website of the United States Government

Aptamer probes for Epigenetic Peptide Targets

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
96220
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
GM093575
Solicitation Year:
N/A
Solicitation Topic Code:
NIGMS
Solicitation Number:
N/A
Small Business Information
ORTHOSYSTEMS, INC.
100 Intrepid Lane Suite 1 Syracuse, NY 13205-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Aptamer probes for Epigenetic Peptide Targets
Agency: HHS
Contract: 1R43GM093575-01
Award Amount: $195,561.00
 

Abstract:

DESCRIPTION (provided by applicant): Epigenetic aberrations underlie the pathogenesis of a number of human diseases that lack clear genetic alterations. For example, mental health diseases such as bipolar disorder and schizophrenia are associated with epigenetic changes in the promoters of enzymes that metabolize neurotransmitters. Other diseases in which epigenetic factors have been shown to play a role include cancer, autism, asthma and reproductive diseases. Gene expression differences in aging monoz ygotic twins suggest that epigenetic drift may be associated with chronic diseases that appear as we age. One of the most promising aspects of epigenomic research is that, unlike genetic aberrations, epigenetic aberrations are potentially reversible, by mo dulating the activities of the enzymes that stabilize or remodel specific chromatin states. In this project a set of epigenetic peptide and protein targets will be screened against libraries of nucleic acids using OrthoSystems new and highly successful ap proach, High Throughput Screening of Aptamers (HTSA), for discovery of DNA/RNA molecules that bind proteins with high affinity and specificity. HTSA aptamer hits will be investigated under standard experimental conditions for sensitivity, cross reactivity and robustness. In Phase II, aptamers that meet or exceed our performance standards will be made available to the re- search community through NIH reagent repositories (limited offering) or for a fee from OrthoSystems, Inc (full product line with attachmen t chemistry.) These aptamer products will serve as low cost, renewable, standar- dized affinity reagents for epigenomic research. This collaborative project will be led by OrthoSystems, Inc. with a subcontract to Syracuse University. PUBLIC HEALTH RELEVANCE: Epigenetic aberrations underlie the pathogenesis of mental health diseases, such as bipolar disorder and schizophrenia, by causing changes in the regulation of genes that produce enzymes to metabolize neuro transmitter molecules. Other dise ases in which epigenetic factors play a role include cancer, autism, asthma and reproductive diseases, and may also be associated with chronic diseases that appear as we age. Many proteins are known to have critical roles in the manner in which DNA is pack ed tightly into chromo- somes or is available for expression of genes. This project will provide new and far more effective tools to measure the degree to which these proteins are modified. Unlike genetic aberrations, epigenetic changes are potentially rev ersible by modulating the activities of the enzymes that stabilize or remodel the packing of DNA in chromosomes.

Principal Investigator:

Mark P. Mcpike
3154435356
MPMCPIKE@ORTHOBIOSYSTEMS.COM

Business Contact:

Mcpike P. Mark
mpmcpike@aptamatrix.com
Small Business Information at Submission:

ORTHOSYSTEMS, INC.
Aptamatrix, Inc. 100 Intrepid Ln SYRACUSE, NY 13205

EIN/Tax ID: 184161892
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No